Efficacy of alternative vs. standard dosing strategies of anti-CD20 monoclonal antibodies in multiple sclerosis: A systematic review and meta-analysis.
Efficacy of alternative vs. standard dosing strategies of anti-CD20 monoclonal antibodies in multiple sclerosis: A systematic review and meta-analysis.
Ida Mohammadi,Shahryar Rajai Firouzabadi,6 Authors,M. Salari
2025 · DOI: 10.1016/j.msard.2025.106668
Multiple Sclerosis and Related Disorders · 0 Citations
TLDR
ADS for anti-CD20 mAbs appear comparable to SDS, and EID does not increase the risk of relapse, MRI activity, disability progression, or NEDA loss.